Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients by Maloney, Ann E & Sikich, Linmarie
© 2010 Maloney and Sikich, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2010:6 749–766
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
749
exPerT OPiNiON
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/NDT.S6614
Olanzapine approved for the acute treatment 
of schizophrenia or manic/mixed episodes 
associated with bipolar i disorder in 
adolescent patients
Ann e Maloney1,2
Linmarie Sikich3
1Maine Medical Center research 
institute, Scarborough, Me, USA; 
2Department of Psychiatry, Tufts 
University School of Medicine, Boston, 
MA, USA; 3Department of Psychiatry, 
University of North Carolina at 
Chapel Hill, Chapel Hill, NC, USA
Correspondence: Linmarie Sikich
room 254, Medical School Wing D, CB 
7160 UNC, 101 Manning Dr, Chapel Hill, 
NC 27514-7160, USA
Tel +919 966 8653/919 966 8655
Fax +919 966 8004
email lsikich@med.unc.edu
Background: Severe and persistent mental illnesses in children and adolescents, such as 
  early-onset schizophrenia spectrum (EOSS) disorders and pediatric bipolar disorder (pedBP), 
are increasingly recognized. Few treatments have demonstrated efficacy in rigorous clinical trials. 
Enduring response to current medications appears limited. Recently, olanzapine was approved for 
the treatment of adolescents with schizophrenia or acute manic/mixed episodes in pedBP.
Methods: PubMed searches were conducted for olanzapine combined with pharmacology, 
schizophrenia, or bipolar disorder. Searches related to schizophrenia and bipolar disorder were 
limited to children and adolescents. The bibliographies of the retrieved articles were hand-checked 
for additional relevant studies. The epidemiology, phenomenology, and treatment of EOSS and 
pedBP, and olanzapine’s pharmacology are reviewed. Studies of olanzapine treatment in youth 
with EOSS and pedBP are examined.
Results: Olanzapine is efficacious for EOSS and pedBP. However, olanzapine is not more 
efficacious than risperidone, molindone, or haloperidol in EOSS and is less efficacious than 
clozapine in treatment-resistant EOSS. No comparative trials have been done in pedBP. 
  Olanzapine is associated with weight gain, dyslipidemia, and transaminase elevations in youth. 
Extrapyramidal symptoms, neuroleptic malignant syndrome, and blood dyscrasias have also 
been reported but appear rare.
Conclusions: The authors conclude that olanzapine should be considered a second-line agent in 
EOSS and pedBP due to its risks for significant weight gain and lipid dysregulation. Awareness 
of the consistent weight and metabolic changes observed in olanzapine-treated youth focused 
attention on the potential long-term risks of atypical antipsychotics in youth.
Keywords: early-onset schizophrenia, pediatric bipolar disorder, antipsychotic
The US Food and Drug Administration (FDA) issued an indication for olanzap-
ine in the treatment of adolescents, 13–17 years old, with schizophrenia or acute 
manic/mixed episodes in bipolar I disorder (BPI) in December 2009. However, the 
FDA also formally stated that clinicians may “consider prescribing other drugs first 
in adolescents” given olanzapine’s increased potential for weight gain and hyperlipi-
demia in adolescents compared with adults. This article reviews the presentation and 
treatment of early-onset schizophrenia (EOS) and pediatric bipolar disorder (pedBP), 
the pharmacology and kinetics of olanzapine, the evidence supporting olanzapine’s 
efficacy in these two serious mental illnesses among children and adolescents, the 
safety and tolerability of olanzapine in pediatric patients, and the probable role of 
olanzapine within the pediatric population compared with the adult population. The Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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information presented in this article was gathered through 
a systematic PubMed review, with searches conducted for 
olanzapine combined with pharmacology, schizophrenia, 
or bipolar disorder. Searches related to schizophrenia and 
bipolar disorder were limited to children and adolescents. The 
bibliographies of key-retrieved articles were hand-checked 
for additional relevant studies. Rigorously, controlled data is 
limited in this population, so observations from nonblinded 
trials will also be presented. All conclusions are those of the 
authors and do not reflect specific recommendations of any 
national organization or government entity.
Early-onset schizophrenia
The incidence of EOS is not well established with epide-
miologic studies. However, a number of geographically 
limited studies focused on hospital admissions have pro-
vided consistent estimates of the incidence in children and 
adolescents. The illness is very uncommon (∼0.3/1000) in 
children younger than 10 years, then increases to approxi-
mately 1.3/1000 between ages 10 and 14 years with an even 
greater increase between 14 and 18 years with incidence 
rates varying between 2.0 and 5.5/1000. Indeed, at least 5% 
of those with schizophrenia become ill prior to 14 years of 
age and up to 20% appear to become ill prior to 18 years 
of age.1–5 The peak age of onset is between 15 and 20 
years in males and between 15 and 25 years in females.6 
Modestly more males experience EOS than females 
(~1.5 males: 1 female).
Diagnostic criteria for EOS are the same as for 
adult-onset criteria except that psychotic symptoms must 
be present prior to age 18 years. However, there are some 
development differences in detailed characteristics of 
symptoms. Specifically, youth are more likely to have multi-
modal hallucinations than adults and frequently personalize 
their hallucinations giving them names that are frequently 
stereotyped, such as “Satan,” “my guardian angel,” or the 
“monster” or derived from visual characteristics, such as 
the “man with no skin”. They seldom have systematized 
or bizarre delusional symptoms, though vague paranoia is 
common. Disorganized thinking is frequently observed.7–10 
Younger individuals may have difficulty recognizing 
their symptoms as abnormal and frequently do not com-
plain spontaneously about hallucinations.11 Youth who 
will experience EOS frequently show greater premorbid 
problems with attention, learning, and socialization than 
individuals who develop schizophrenia as adults. The onset 
of symptoms in EOS is most often insidious.12,13 Youth with 
EOS who participate in clinical trials often have more severe 
psychiatric symptoms, greater neurocognitive deficits, and 
more pronounced gray matter loss than research participants 
with adult-onset schizophrenia.14–18 Individuals with EOS 
are much less likely to have a good outcome than individuals 
with adult-onset schizophrenia, with the majority having 
poor or very poor outcomes.13,19–21
Treatment of EOS has traditionally been based on the 
pharmacologic treatments used for adult-onset schizo-
phrenia. There is little systematic use of psychotherapeutic 
strategies in this population.22 Efficacy of antipsychotics has 
been assumed to be generally similar in youth and adults. 
This view was bolstered by small studies of first-generation 
antipsychotics (FGAs), including haloperidol, thioridazine, 
thiothixene, and loxapine that showed relatively high rates 
of response.9,23,24 However, considerable sedation was also 
observed, and there were concerns about extrapyramidal 
symptoms (EPS), which appear to be somewhat more 
prevalent in youth than adults.25 In the 1990s, a pivotal 
trial was done showing that youth with treatment-resistant 
schizophrenia had a robust response to clozapine, the proto-
typic second-generation antipsychotic (SGA) introduced in 
1989.26 However, significant adverse effects were frequent 
and limited the use of this agent.
As other SGAs have been introduced and approved 
for use in adults with schizophrenia over the past 
20 years (Table 1), including olanzapine in 1996,   clinicians 
embraced them hoping both for greater efficacy and fewer 
adverse effects than the FGAs or clozapine. There was par-
ticularly great enthusiasm for olanzapine because its phar-
macologic profile was most similar to clozapine’s and it was 
less prone to EPS than risperidone, which has more potent 
dopamine D2 antagonism. Enthusiasm for olanzapine was 
further increased by a study of olanzapine vs haloperidol 
in 263 patients with first-episode schizophrenia, who were 
followed for 2 years.27 Although there were no difference in 
symptom reduction between the two agents in a last obser-
vation carried forward analysis, a mixed-model analysis 
demonstrated an acute advantage for olanzapine in Positive 
and Negative Syndrome Scale (PANSS) total score, PANSS 
negative and general symptoms, and a depression rating 
scale. Results of the 2-year data found that patients treated 
with olanzapine were significantly more likely to enter 
remission (olanzapine 57%, haloperidol 44%, P , 0.036) 
and continued treatment for a longer period of time (olan-
zapine 322 days, haloperidol 230 days, P , 0.0085) than 
those treated with haloperidol.28 Perhaps most importantly, 
the imaging component of this study found that individuals 
treated with haloperidol experienced significant decreases Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Current FDA indications for second-generation antipsychotics
Drug Indication Approval date
Aripiprazole Schizophrenia in adults November 15, 2002
Maintenance treatment of adult schizophrenia August 28, 2003
Acute adult manic/mixed BP1 September 29, 2004
Maintenance treatment of adult BP1 March 1, 2005
Schizophrenia in 13–17 year olds October 29, 2007
Adjunctive treatment in adult major depression November 16, 2007
Acute monotherapy or adjunctive therapy with lithium or valproate in manic/mixed  
episodes of BP1 in 10–17 year olds
February 27, 2008
irritability in autism in 6–17 year olds November 19, 2009
Asenapine Schizophrenia in adults BP1 in adults August 14, 2009
Clozapine Treatment-resistant schizophrenia September 26, 1989
emergent suicidality in schizophrenia or schizoaffective disorder December 18, 2002
Olanzapine Acute psychotic disorders in adults September 30, 1996
Manic/mixed in BP1 adults March 17, 2000
Maintenance treatment in schizophrenia in adults November 9, 2000
Adjunctive use with lithium or valproate in acute mania/mixed BP1 July 10, 2003
Maintenance treatment in adult BP1 January 14, 2004
13–17 year olds with schizophrenia may consider other drugs first due to weight gain and  
dyslipidemia
December 4, 2009
13–17 year olds with mania/mixed BP1 as monotherapy or adjunct to valproate  
or lithium may consider other drugs first given weight gain/dyslipidemia
Quetiapine Psychotic disorders in adults September 26, 1997
Monotherapy or adjunctive therapy in BP1 in adults January 12, 2004
Major depression associated with BP1 in adults October 20, 2006
Maintenance treatment in adult BP1 as adjunct to lithium or valproate May 13, 2008
Treatment of schizoprenia in 13–17 year olds  
Acute treatment of mania/mixed BP1 in 10–17 year olds either as monotherapy or adjunctive therapy
December 2, 2009
risperidone Treatment of schizophrenia in adults December 29, 1993
Long-term treatment of schizophrenia in adults March 3, 2002
Monotherapy or adjunctive therapy to lithium or valproate in adults with BP1 December 4, 2003
irritability in autism in 5–16 year olds October 6, 2006
Schizophrenia in 13–17 year olds  
BP1 in 10–17 year olds
August 22, 2007
Ziprasidone Schizophrenia in adults February 5, 2001
Monotherapy in manic/mixed in BP1 in adults August 19, 2004
Maintenance treatment as adjunct to lithium or valproate in BP1 in adults November 20, 2009
Note: See http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyinformationforPatientsandProviders/ucm094303.htm. 
Abbreviations: FDA, US Food and Drug Administration; BP1, bipolar 1 disorder.1
in brain gray matter volume, whereas neither those treated 
with olanzapine nor a healthy control group showed any 
changes.29 Optimism that olanzapine may have particular 
advantages for treating youth with psychotic symptoms was 
also heightened with results published from a small pilot 
study comparing olanzapine, risperidone, and haloperidol 
in the treatment of psychotic youth aged 8–20 years.30 
This study in the pediatric population found a modest 
numeric, but not statistically significant, advantage for 
olanzapine in the response rate (olanzapine 88%, risperi-
done 74%, haloperidol 53%), premature drop-out (olanzap-
ine 2/16, risperidone 9/19, haloperidol 7/15, P = 0.058), and 
time to treatment discontinuation (olanzapine 7.4 weeks, 
risperidone 6.3 weeks, haloperidol 5.7 weeks). However, 
the same trial also suggested that adverse events with the 
SGAs may be more common and more severe in youth 
than in adults. Proponents of   olanzapine also focused on 
results from the Clinical Antipsychotic Trials of Interven-
tion Effectiveness (CATIE) study in 1,493 adults with 
chronic schizophrenia. Although there were few clinically 
significant differences among SGAs and between SGAs 
and FGAs in the CATIE study, olanzapine had marginally 
greater benefits as reflected by greater initial reductions in 
PANSS, greater initial improvements in the Clinical Global 
Impression (CGI), lower rate of hospitalization due to 
psychiatric exacerbation, lower discontinuation rates, and 
longer time to treatment discontinuation.29 As discussed 
in detail later, the Treatment of Early Onset Schizophrenia Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
752
Maloney and Sikich
Spectrum Disorders (TEOSS) study did not identify any 
advantage for olanzapine compared with risperidone or 
molindone in children and adolescents with schizophre-
nia,31 suggesting a potential difference in olanzapine’s 
efficacy during different stages of schizophrenia.
Pediatric bipolar disorder
Similar to EOSS, there are few epidemiologic studies that 
rigorously examine the incidence of pedBP. The primary 
exception to this is a recent small study done in which 3,021 
community subjects (14–24 years of age) in Germany were 
reassessed 10 years later.32 This study found that approxi-
mately 1.2% of the youth had experienced a manic or hypo-
manic episode by 12 years of age and approximately 4.5% 
had experienced a manic or hypomanic episode by 18 years 
of age. Manic episodes occurred with similar frequency in 
males and females, whereas hypomanic episodes were about 
twice as common in females as males and as mania in either 
gender. Rates dramatically increased during adolescence. 
Further, 9% of those with a major depressive episode prior 
to age 17 years subsequently developed bipolar disorder, 
which was significantly greater than those with later onset 
of depression. The incidence of manic and hypomanic epi-
sodes in this study is greater than the prevalence of bipolar 
1 disorder in adults (4.5% lifetime and 2.8 annual),33 which 
is typically reported in larger epidemiologic studies, likely 
due to the expert clinical interviewers used in the German 
study. In a recent multisite treatment study of 3,658 adults 
with bipolar disorder, 29% reported onset before age 13 and 
67% reported onset by age 18.34 A study of 119 individuals 
consecutively admitted to a psychiatric hospital in Norway 
with bipolar disorder found that 13.5% had onset during 
childhood and 61.6% had onset prior to age 20 and that those 
who reported an affective temperament had earlier onset.35 
The period of peak onset appears to be in 12 and 22 years of 
age.32 It should be noted that there has been approximately 
a 40-fold increase in the recognition of bipolar disorder in 
children and adolescents over the past decade in the US.36
Diagnosis of pedBP has been somewhat contentious with 
many critics arguing that the disorder is misdiagnosed in a 
large number of youth. The controversy seems related to 
two major issues.37 First, in children and many adolescents, 
the pattern of cycling within a given episode and the dura-
tion of episodes appear quite different between youth and 
adults. Youth frequently have a large number of cycles or 
mood swings within a single episode of illness. Often, this 
cycling can occur multiple times a day even though there 
may be months without an extended euthymic period that 
would signal the end of the episode. In contrast, most adults 
demonstrate a fairly consistent mood state throughout any 
given episode. In pedBP, a single episode will often last for 
a very extended period giving the appearance of a chronic 
condition, whereas in adults, episodes are usually limited to a 
few weeks.38,39 Second, children and, to a lesser extent, adoles-
cents frequently experience mixed states of mania and depres-
sion, whereas adults less frequently show such states. The 
sensitivity and specificity of various individual symptoms of 
mania and their differential manifestations in other childhood 
diagnoses are eloquently reviewed by Youngstrom et al.37 
Further, there are developmental differences within pedBP, 
with children frequently showing greater comorbidity with 
attention deficit hyperactivity disorder. Childhood-onset 
bipolar disorder is associated with greater mood lability, 
irritability, and hallucinations than adolescent-onset bipolar 
disorder. However, many highly concerning symptoms, 
including psychotic symptoms, suicidality, grandiosity, and 
decreased need for sleep, increase during adolescence, often 
to a greater extent in those with childhood-onset bipolar 
disorder than those with adolescent-onset bipolar disorder.40 
In addition, there is more controversy about the boundaries 
of the bipolar spectrum in the pediatric population than in 
the adult population. Criteria for various potential disorders 
within the spectrum have been most explicitly defined by 
Leibenluft and colleagues.41 These criteria subdivide bipolar 
NOS (Not Otherwise Specified) into categories in which a 
sufficient number of criteria are not met, symptoms do not 
appear to have sufficient duration, irritability is primary mood 
state, and moods are severely dysregulated in the context 
of many symptoms of hyperarousal but in the absence of 
psychotic symptoms or elation. The latter category, called 
severe mood dysregulation, appears most common and is 
likely to be highly heterogeneous.
Most of the current longitudinal studies of pedBP involve 
limited follow-up and focus primarily on rates of remis-
sion and relapse.42–46 However, adults with childhood-onset 
bipolar disorder appear to experience significantly worse 
outcomes, including more rapid relapse, less euthymia, and 
poorer functioning and quality of life than those with adult-
onset bipolar disorder.34 In addition, rates of suicidality and 
suicide attempts are particularly high in adolescents with 
bipolar disorder (72%–76% and 31%–44%, respectively).47,48 
Suicidality in bipolar youth appears to be increased in those 
with psychotic symptoms.49
Treatment for pedBP has evolved from treatment of 
adults with bipolar disorder with specific treatment studies 
for pedBP limited until the past decade. Until 2007, lithium Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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was the only mood-stabilizing agent specifically approved 
by the FDA for the treatment of acute mania in adolescents. 
However, this indication does not reflect specific evalua-
tion of the efficacy and safety of lithium in adolescents. 
Despite this, valproate was probably the most widely used 
mood stabilizer in the pediatric population until the SGAs 
were introduced in the 1990s because of its availability in a 
sprinkle formulation, more favorable therapeutic index (ratio 
of toxic dose to therapeutic dose), and less onerous side-
effect profile compared to lithium. Carbamazepine was also 
used to some extent. As other antiepileptic drugs, including 
oxcarbamazepine, gabapentin, topiramate, and lamotrigine, 
began to be used in adults, they were embraced for use in 
the pediatric population because they frequently did not 
require monitoring of blood levels. Lithium was among 
the first agents specifically studied in youth. Lithium led to 
greater reductions in the substance use and improvements 
in the Clinical Global Impressions Scale than placebo 
in a sample of 25 adolescents with both bipolar disorder 
and substance abuse.50 A subsequent open trial found that 
lithium, in conjunction with an antipsychotic in nearly 50% 
of the cases, led to reduction in acute manic symptoms in 
approximately two-thirds of adolescents with acute mania 
and remission in about one-quarter of the participants.51 
Further, although no placebo-controlled trials of lithium for 
mania have been completed in pedBP, one study evaluated 
the rapid discontinuation of lithium by replacement with 
placebo or continuation of lithium over 2 weeks in youth who 
had responded to therapeutic doses of lithium for at least 4 
weeks.52   Surprisingly, more than 50% of the participants in 
both the lithium and the placebo groups experienced signifi-
cant symptom exacerbation. In addition, among adolescents 
with both psychotic and manic symptoms, long-term treat-
ment with antipsychotics in addition to lithium was generally 
required to maintain the initial response to treatment.53
Other open-label studies in pedBP have described 
significant responses to valproate and carbamazepine, as 
well as lithium.54,55 However, in many of these trials, the 
majority of youth were concurrently taking antipsychotics 
or other mood stabilizers. In the only randomized but open 
monotherapy trial of mood stabilizers published to date, 
more than 50% of the participants did not respond to the 
initially randomized mood stabilizer though 80% of these 
responded to combined treatment with two mood stabiliz-
ers.56 Studies exploring discontinuation of one mood stabi-
lizer after stabilization on combination treatment support 
are consistent with the requirement of combination therapy 
for many youth with bipolar disorder.57 Significantly, recent 
placebo-controlled trials of mood stabilizers published to 
date have failed to demonstrate efficacy of either oxcarbam-
azepine or valproate.58,59
Antipsychotics were initially used adjunctively in 
  treatment-resistant bipolar disorder in adults.   Clozapine appeared 
particularly effective. Subsequently, other   second-generation 
agents were studied as a treatment of all phases of bipolar 
disorder, particularly risperidone and olanzapine. Initially, antip-
sychotics were used as adjunctive treatment to mood stabilizers 
and appeared to have increased benefit with no major toler-
ability issues.60 A blinded, placebo-controlled trial of quetiapine 
adjunctive therapy demonstrated significantly greater reduc-
tion in mania scores and greater response rate than valproate 
monotherapy.61 An open-label trial of olanzapine monotherapy 
was also very promising.62 Subsequently, a double-blind trial 
comparing quetiapine with valproate demonstrated superior 
response and remission rates with quetiapine even though 
reductions in mean mania scores did not differ.63 Since that time, 
placebo-controlled trials of each of the atypical antipsychotics 
other than clozapine – olanzapine,64 aripiprazole,65 risperidone,66 
and quetiapine67 – have found that each active agent reduced the 
Young Mania Rating Scale (YMRS)68 score to a significantly 
greater extent than placebo over 3 weeks among youth expe-
riencing acute manic/mixed episodes. Based on these results, 
risperidone and aripiprazole were approved for the acute treat-
ment of mixed and manic episodes of bipolar disorder in youth 
of 10–17 years old, and olanzapine and quetiapine were approved 
in adolescents. There has also been one small, double-blind pilot 
study that failed to show any advantage for quetiapine over 
placebo in the treatment of depression within pedBP.69 Notably, 
a large National Institute of Mental Health (NIMH)-sponsored 
comparative trial of risperidone, valproate, and lithium has been 
recently completed and should be reported soon. In summary, 
there is evidence for significant benefit from antipsychotics in 
the treatment of mixed and manic states in youth and a lack of 
efficacy of valproate and oxcarbamazepine. There is no empiric 
evidence yet of an effective treatment for depression or relapse 
prevention in youth with bipolar disorder.
Olanzapine pharmacology  
and pharmacokinetics
Olanzapine is a thienobenzodiazepine analog that binds 
to a large number of neurotransmitter receptors, including 
the dopamine D1, D2, and D4 receptors, serotonin 5-HT2A, 
5-HT2C, 5-HT6, and 5-HT3 receptors, histamine H1 receptor, 
muscarinic receptors, α- and β-adrenergic receptors, γ-amino 
butyrate (GABA)a1 receptor, and the benzodiazepine bind-
ing sites.70 Its binding profile is more similar to clozapine’s Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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than any other atypical antipsychotic. Olanzapine’s antip-
sychotic and mood-stabilizing effects are likely the result 
of potent antagonism at dopamine and serotonin receptors, 
with affinity constants ranging from 4 nM to 31 nM. It also 
binds with high affinity to H1 and M1 receptors. The drug 
binds with moderate affinity to 5-HT3 and M2–5 receptors and 
binds weakly to GABA, benzodiazepine binding sites, and 
β-adrenergic receptors. It is also likely that olanzapine regu-
lates various signaling pathways within the brain, including 
the extracellular signal-related kinases (ERK1/2), particularly 
with long-term treatment.71 Developmental differences in 
the binding profile of olanzapine have not been examined 
to our knowledge. Olanzapine’s metabolic adverse effects 
have been hypothesized to relate to its histaminergic binding 
profile.72,73 In addition, olanzapine-associated weight gain has 
been linked to genetic variations in the 5-HT2A, 5-HT2C, and 
β3-adrenergic receptor, leptin, and the G-protein β3 subunit 
genes.74–76 The anticholinergic side effects are likely related 
to the muscarinic antagonism and the orthostatic hypotension 
related to antagonism at α-adrenergic receptors.
Olanzapine is well absorbed after oral administration and 
reaches maximal levels in about 5 hours in adults. Eating 
does not appear to affect olanzapine’s bioavailability. It is 
excreted in the urine (65%) and feces (35%) over the course of 
approximately 7 days.77 It is metabolized extensively within 
the liver undergoing glucuronidation (to yield the primary 
metabolic products), allylic hydroxylation, oxidation, and 
dealkylation. Oxidation occurs primarily via the CYP1A2 
cytochrome P450 enzyme (Figure 1).78
Levels are affected by smoking (leading to ∼30% reduction 
in plasma level), gender (women have ∼85% increased plasma 
levels), carbamazepine (decreased plasma levels), and fluvox-
amine and other selective serotonin reuptake inhibitors (SSRIs) 
(increased plasma levels).79–84 The elimination half-life ranges 
from about 27 hours in smokers to 37 hours in nonsmokers. 
Plasma levels of olanzapine appear to increase slowly over a 
period of months with a slightly slower time course in women 
compared with men.81,85 There are no significant differences 
that appear in bioavailability or half-life of oral tablet and the 
orally disintegrating form of olanzapine.86
In general, the pharmacokinetics of olanzapine are similar 
in youth and adults.87,88 Adolescents experience considerable 
intra-individual variability across time despite stable dosing, 
which appears somewhat greater in adolescents than adults.85,89 
The concentration-to-dose ratio of olanzapine appears gener-
ally linear.78 However, adolescents appear to have a higher 
(∼34%) concentration-to-dose ratio than adults even after 
adjustment for weight.90
Olanzapine efficacy in EOS
The  first  report  of  olanzapine  treatment  in  youth 
with schizophrenia was an open trial done in eight youth 
with childhood-onset, who had not responded to prior tri-
als with antipsychotics other than clozapine.91 In this study, 
there was modest improvement in overall symptoms and 
negative symptoms but no significant change in positive 
symptoms. A comparison group of 15 treatment-resistant 
youth exposed to clozapine demonstrated greater benefits 
only after 6 weeks of treatment. In a trial of 15 children 
younger than 13 years of age, 10 showed moderate or marked 
improvements in psychotic symptoms.92 However, all patients 
who had been previously exposed to antipsychotics did not 
improve. In contrast, an open-label study of 9 other treatment-
resistant children found significant improvements at 12 weeks 
from baseline in all symptom domains and found that eight 
of the children sustained improvements over the course 
of 1 year.93 However, two double-blind studies comparing 
clozapine and olanzapine in youth with treatment-resistant 
schizophrenia had similar findings to the initial report.94,95 
In each of these trials, clozapine resulted in greater reductions 
in negative symptoms and, in the most recent trial, greater 
response rates.
Olanzapine has also been tested in youth with schizo-
phrenia, who are not treatment resistant. The initial open 
trials for these youth were done in 2003, and included 20 
youth (6–15 years old) and 16 adolescents (12–17 years old) 
respectively.96,97 Both trials showed significant improvements 
in symptoms, illness severity, and function within 6–8 weeks 
of initiating treatment. However, improvements in nega-
tive symptoms were reported to occur later in the trial that 
included children and adolescents.97 In the Ross trial, 74% 
of the youth were considered responders and retained that 
response status after 1 year of treatment. A similar response 
rate has been achieved in other open-label trials including a 
large 6-week trial with an additional 18-week follow-up in 
96 adolescents.98,99
Subsequently, olanzapine was openly compared with 
risperidone and haloperidol in physicians’ choice (nonran-
domized) treatment of 43 adolescents with schizophrenia.100 
There were no apparent differences in antipsychotic efficacy 
between the three treatments with significant benefit within 
4 weeks of starting treatment. However, haloperidol was 
associated with greater emergence of depressive symptoms. 
A more recent trial that involved 16 adolescents with psy-
chotic symptoms treated with olanzapine, 50 treated with ris-
peridone, and 18 treated with quetiapine also failed to detect 
differences between the antipsychotic efficacy of the agents Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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at 6 months when baseline psychopathology scores were 
included as a covariate in the analysis.101 However, olanzapine 
consistently showed the greatest number of reductions in all 
types of psychotic symptoms. A double-blind, randomized 
trial of acute psychotic symptoms in 50 youth with either 
affective or schizophrenic psychoses also failed to show 
statistically significant differences between treatments.30 In 
this study, the olanzapine group showed the greatest response 
rate (88% compared with 74% for risperidone and 53% for 
haloperidol) and longest duration of treatment. However, the 
numeric superiority of olanzapine may have partially reflected 
the preponderance of youth with affective psychoses (69%) 
in the olanzapine group in contrast with the other two groups 
where schizophrenic diagnoses were more common. A larger 
(n = 116), placebo-controlled, randomized trial comparing 
olanzapine (n = 34) with risperidone (n = 41) and molindone 
(n = 40) exclusively in youth with EOS, known as the TEOSS 
trial, again found no statistically significant or numeric dif-
ferences in symptom reduction between the agents.31,102 How-
ever, in contrast to the earlier study, olanzapine treatment was 
sustained for a numerically shorter period, and numerically 
fewer participants treated with olanzapine responded than 
those treated with the other two agents (olanzapine: 34%; 
risperidone: 46%, molindone: 50%).
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One double-blind, placebo-controlled trial of   olanzapine 
has been done in adolescents 13–17 years old with 
  schizophrenia.103 In this international multisite trial, 72 youth 
were treated with olanzapine and 35 with placebo. Olanzapine 
  treatment led to much greater and highly   statistically   significant 
improvements in the CGI Severity score (P = 0.004), the 
Brief Psychiatric Rating Scale for Children (BPRS-C)104,105 
(P = 0.003), the PANSS total score (P = 0.005), and posi-
tive symptom scale (P = 0.002), but not negative symptoms. 
However, a reviewer at the FDA raised concerns about the 
study because the positive results of the study were primar-
ily driven by the Russian sites not the US sites.106 Although 
the BPRS-C symptom reduction seen with olanzapine was 
similar in both sites (US: −21, Russia: −17), there were dra-
matic differences in the magnitude of reduction with placebo 
(US: −15; Russia: −3), resulting in markedly different changes 
in the P value (US: P = 0.258; Russia: P = 0.003). Importantly, 
an FDA audit of two Russian sites found no concerns about 
the conduct of the study. The FDA Director of the Division of 
Psychiatry Products, Dr. Thomas Laughren, believed that these 
differences between sites probably reflected differences in the 
availability of care for youth with schizophrenia between the 
two countries and greater heterogeneity of the study popula-
tion at US sites and also believed that olanzapine should be 
approved in adolescent schizophrenia.
Olanzapine efficacy in pedBP
Olanzapine was initially reported to be useful for treating 
mania and mixed states in an 8-week, open-label prospective 
study of 23 youth aged 5–14 years old.62 There was a highly 
significant improvement in the YMRS107 (−19.0, P , 0.001) 
and overall response rate (defined as $30% reduction in 
YMRS and CGI-Severity score of mild or less severe) was 
61%. Subsequently, DelBello and colleagues108 examined the 
effects of olanzapine treatment on brain neurochemistry using 
proton spectroscopy in 19 adolescents with mania, who were 
scanned prior to beginning treatment and on days 7 and 28 of 
treatment. Ten healthy control adolescents were scanned to 
assess normal variability in brain metabolites over 4 weeks. 
Ten (58%) of the participants had remission of symptoms. 
All participants showed increases in ventral prefrontal 
choline. However, those with remission showed significant 
increases in medial ventral prefrontal N-acetyl aspartate 
within 7 days of treatment (P = 0.05) and had increased 
baseline levels of ventral prefrontal choline compared with 
nonremitters (P , 0.001). Because N-acetyl aspartate is 
believed to reflect neuronal vitality, this finding suggests 
potential beneficial changes in brain structure among some 
adolescents whose mania is treated with olanzapine. The only 
randomized, placebo-controlled trial of olanzapine for the 
treatment of manic and mixed states in adolescents (13–17 
years old) was conducted by Eli Lilly.64 In that study, 107 
youth were treated with olanzapine and 54 with placebo for 
3 weeks. The olanzapine group showed significantly greater 
reduction in the YMRS than the placebo group (olanzapine: 
−17.7,   placebo: −10.0, P , 0.001).   Olanzapine also led to 
dramatically higher response and remission rates than placebo 
(olanzapine: 48.6% and 35.2%, placebo: 22.2% and 11.1%, 
P = 0.002 and P = 0.001, respectively). We are unaware of 
any trials that have compared the efficacy of olanzapine and 
other mood-stabilizing agents in the pediatric population.
Olanzapine safety 
and tolerability in youth
Despite the evidence supporting the efficacy of olanzapine in 
EOS and pedBP, concerns about excessive weight gain with 
olanzapine emerged early. As olanzapine was used more fre-
quently in youth, additional concerns about metabolic abnor-
malities, liver function abnormalities, sedation, and prolactin 
elevations emerged. Subsequently, the safety and tolerability 
of olanzapine in the pediatric population have been examined 
in comparison to adults treated with olanzapine. An early 
postmarketing surveillance study examined the database for 
olanzapine through March 31, 2000, linked it with patient 
exposure estimates during the same period provided by Eli 
Lilly, and divided the analysis into children (birth to 9 years), 
adolescents (10–19 years), and adults (20 years and older).109 
The study found that extrapyramidal syndrome complaint 
risks were similar across development, and tardive dyskinesia 
complaint risks were comparable in adolescents and adults. 
Overrepresented complaints in children included weight gain, 
liver function abnormalities, sedation and   tardive dyskinesia. 
Overrepresented complaints in adolescents included weight 
gain, liver function abnormalities, sedation, and prolactin 
increases. A more recent analysis done by Eli Lilly compared 
the weight and metabolic data from 454 adolescents aged 
13–17 years old exposed to olanzapine (primarily under 
open conditions) for as long as 32 weeks to the pooled 
weight data from 7,847 adults treated with olanzapine for 
up to 32 weeks and pooled metabolic data from adults from 
four trials.107 The adolescents experienced more frequent 
and severe weight gain than the adults (.7% weight gain 
in 65.1% of adolescents and 35.6% of adults, P , 0.001; 
mean weight gain 7.4 kg in adolescents and 3.2 kg in adults, Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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P , 0.001). Adolescents were also much more likely to 
develop hyperprolactinemia (adolescents: 55.5%, adults: 
29.0%, P , 0.001). However, in contrast, adults had more 
adverse metabolic changes than the adolescents with 11.8% 
of adults and 3% of   adolescents moving from normal or 
impaired glucose to high glucose (P , 0.001), and 31%–38% 
of adults compared with 17%–21% of adolescents developed 
borderline dyslipidemias (P , 0.001 for all). This likely 
reflects other lifestyle and metabolic problems including 
lower insulin reserves in the adults.
The largest and most definitive data review of olanzapine’s safety 
and tolerability in adolescents, pools all six Eli Lilly-sponsored 
trials of olanzapine in a total of 179 youth studied under placebo-
controlled conditions for up to 6 weeks and 454 youth exposed 
to olanzapine (primarily under open conditions) for as long as 
32 weeks.110 There have also been some trials that compared 
adverse effects observed in youth treated with olanzapine or 
other antipsychotics, including data between 45 and 52 weeks 
of exposure.30,31,93,101,102,111–115 We will examine each of the main 
adverse effects observed with olanzapine separately.
Weight gain
In the Eli Lilly placebo-controlled adolescent database, 
youth gained 3.9 kg when treated with olanzapine compared 
with 0.2 kg when treated with placebo (P , 0.001). In the 
adolescent-exposure database, the overall weight gain was 
7.4 kg, with nearly two-thirds gaining more than 7% of 
their baseline weight and a 13.3 percentile increase in body 
mass index (BMI), which is a more appropriate measure of 
increased size in youth. Overall, 4% of adolescents withdrew 
from treatment because of weight gain. In examining the time 
course of weight gain, there appears a marked reduction in 
the slope of weight gain after 4 weeks of treatment.110 Similar 
findings of rapid weight gain followed by slower weight gain 
have been observed in other trials.96,102,111,114
In the comparative studies, olanzapine consistently 
demonstrated the greatest weight gain both acutely and with 
more extended use as summarized in Table 2. In almost all 
cases, it has led to significantly more weight gain than other 
antipsychotics with a very high level of significance. Fur-
ther, in contrast with the adult literature, studies that directly 
compare clozapine and olanzapine treatment in youth have 
found that clozapine increases weight to a lesser or equivalent 
extent than   olanzapine does.95,113,114 One study examining 
65 youth treated with olanzapine, clozapine, or risperidone 
found elevations in parents’ and patients’ pretreatment BMIs. 
Female gender and younger age when treated were associated 
with the magnitude of antipsychotic-associated weight gain 
independent of medication. Further, individuals with low 
pretreatment BMIs initially show more rapid weight gain 
than their heavier peers even though total weight gain with 
treatment is less.116
Glucose metabolism
In the Eli Lilly placebo-controlled database, olanzapine-
treated youth showed a 3.6 mg/dL (0.2 mmol/L) increase 
in fasting glucose, whereas placebo-treated youth showed a 
similarly sized decrease. Although not clinically significant, 
this finding was highly statistically significant (P , 0.001). 
Further, 3% of adolescents in the exposure database moved 
from normal or borderline glucose levels into the diabetic 
range.110 Increases in fasting glucose with olanzapine treat-
ment ranging from 0.6 to 10 mg/dL have been reported 
in several other pediatric trials (Table 2).30,31,95 A study of 
45 antipsychotic- naïve youth treated with olanzapine found 
significant increases in glucose, insulin, and insulin resistance 
(measured with homeostasis model assessment–insulin 
resistance [HOMA-IR]) with P values between 0.02 and 
0.03.115 There have also been multiple case reports of youth 
developing diabetes during olanzapine treatment.117–120 It is 
clear that youth are less likely to rapidly develop diabetes as 
a consequence of olanzapine treatment than adults because 
most teens have large insulin reserves. It is not yet clear to 
what extent these increases in glucose persist with sustained 
treatment.
Lipid metabolism
In the Eli Lilly database, youth treated with olanzapine 
showed increases in total cholesterol and triglycerides 
relative to their peers treated with placebo [cholesterol 
11.7 mg/dL (0.03 mmol/L) compared to no change and 
triglycerides 26.7 mg/dL (0.03 mmol/L) compared to 
a decrease of 8.9 mg/dL (−0.1 mmol/L); P = 0.002 and 
P = 0.007, respectively]. Those in the exposure data-
base showed identical changes. Approximately one-fifth 
of the patients developed borderline elevations in total 
cholesterol (.200 and ,240 mg/dL), low-density lipo-
proteins (LDL cholesterol .130 and ,160 mg/dL), and 
triglycerides (.150 and ,200 mg/dL), and 17.8% devel-
oped hypertriglyceridemia.110 Interestingly, changes in lipid 
levels were slightly less in the study of antipsychotic-naïve 
youth ranging from 11.5 mg/dL for LDL cholesterol to 
24.3 mg/dL for triglycerides with all P values less than 
0.004.115 Similar changes have been reported in other small Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Table 2 reported weight and metabolic changes with pediatric olanzapine treatment
Parameter study Treatment 
duration
Olanzapine N Observed changes P value 
between drugs
Olanzapine Other agents
Weight gain
Lilly placebo database110 3–6 wk 179 3.9 kg Placebo 0.2 kg P , 0.001
Lilly total exposure database110 up to 32 wk 450 7.4 kg
Kumra et al91 8 wk 8 3.4 kg
Frazier et al62 8 wk 23 5 kg
ratzoni et al111 12 wk 21 7.2 kg risperidone 3.9 kg 
Haloperidol 1.1 kg
P = 0.02
ross et al97 6 wk 19 3.8 kg
12.8 kg/12 mo
Findling et al96 8 wk 16 6.5 kg
Mozes et al93 12 wk 9 6.1 kg
Sikich et al30 8 wk 16 7.2 kg risperidone 4.9 kg 
Haloperidol 3.6 kg
P = 0.0009
Shaw et al94 8 wk 12 3.6 kg Clozapine 3.8 kg
Mozes et al112 12 wk 12 5.8 kg risperidone 4.5 kg
Fleischhaker et al113 6 wk 15 4.6 kg risperidone 2.8 kg 
Clozapine 2.5 kg
P = 0.03
Quintana et al98 10 wk 16 6.2 kg
Sikich et al31 8 wk 35 6.1 kg risperidone 3.6 kg 
Molindone 0.3 kg
P = 0.0001
Kumra et al95 12 wk 21 BMi 0.7 kg/m2 Clozapine 0.7 kg/m2
Castro-fornieles et al101 24 wk 16 11.7 kg risperidone 6.1 kg 
Quetiapine 6.0 kg
P = 0.02
Dittmann et al99 6 wk 96 5.1 kg
24 wk 32 11.7 kg
Fleischhaker et al114 45 wk 8 16.2 kg risperidone 7.2 kg 
Clozapine 9.5 kg
Correll et al115 12 wk 45 8.5 kg risperidone 5.3 kg 
Quetiapine 6.1 kg 
Aripiprazole 4.4 kg
Fasting glucose
Lilly placebo database110 3–6 wk 179 3.6 mg/dL Placebo −3.6 mg/dL P , 0.001
Lilly total exposure 
database110
up to 32 wk 450 1.8 mg/dL
Sikich et al30 8 wk 16 10.0 mg/dL risperidone −7.9 mg/dL 
Haloperidol −0.3 mg/dL
Sikich et al31 8 wk 35 0.6 mg/dL risperidone 1.2 mg/dL 
Molindone 0.9 mg/dL
Kumra et al95 12 wk 21 3.6 mg/dL Clozapine 4.5 mg/dL
Correll et al115 12 wk 45 3.1 mg/dL risperidone 1.1 mg/dL 
Quetiapine 2.6 mg/dL 
Aripiprazole 0.5 mg/dL
HOMA-IR
Sikich et al31 8 wk 35 1.2 risperidone 0 
Molindone 0.5
Correll et al115 12 wk 45 0.62 risperidone 0.2 
Quetiapine 0.35  
Aripiprazole 0.55
Total cholesterol
Lilly placebo database110 3–6 wk 179 11.7 mg/dL Placebo 0.0 P = 0.002
Lilly total exposure  
database110
up to 32 wk 450 7.8 mg/dL
Sikich et al31 8 wk 35 19.9 mg/dL risperidone10.2 mg/dL  
Molindone 0 mg/dL
P , 0.002
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Table 2 (Continued)
Parameter study Treatment 
duration
Olanzapine N Observedchanges P value 
between drugs
Olanzapine Other agents
Kumra et al95 12 wk 21 17.2 mg/dL
Correll et al115 12 wk 45 15.6 mg/dL risperidone 3.5 mg/dL  
Quetiapine 9.1 mg/dL 
Aripiprazole 2.8 mg/dL
LDL cholesterol
Lilly placebo database110 3–6 wk 179 7.8 mg/dL Placebo 0 mg/dL P = 0.002
Lilly total exposure database110 up to 32 wk 450 7.8 mg/dL
Sikich et al30 8 wk 16 7.6 mg/dL risperidone 2.9 mg/dL  
Haloperidol 0.1 mg/dL
Sikich et al31 8 wk 35 14.7 mg/dL risperidone −9.6 mg/dL  
Molindone 0.5 mg/dL
P = 0.003
Correll et al115 12 wk 45 11.5 mg/dL risperidone 0.2 mg/dL  
Quetiapine 3.9 mg/dL  
Aripiprazole 7.4 mg/dL
Triglycerides
Lilly placebo database110 3–6 wk 179 26.7 mg/dL Placebo −8.9 mg/dL P = 0.007
Lilly total exposure database110 up to 32 wk 450 26.7 mg/dL
Sikich et al30 8 wk 16 26 mg/dL risperidone −2 mg/dL  
Haloperidol 22 mg/dL
Sikich et al31 8 wk 35 21.6 mg/dL risperidone 7.1 mg/dL  
Molindone −5.8 mg/dL
Kumra et al95 12 wk 21 11.4 mg/dL Clozapine 16.8 mg/dL
Correll et al115 12 wk 45 24.3 mg/dL risperidone 9.7 mg/dL  
Quetiapine 37.0 mg/dL  
Aripiprazole −2.4 mg/dL
studies that included individuals previously exposed to 
antipsychotics (Table 2).30,31,95 Again there is limited infor-
mation about the long-term course of these lipid changes.
Liver dysfunction
The Eli Lilly databases also report significant elevations in 
liver enzymes associated with olanzapine treatment. Alanine 
aminotransferase (ALT) increased by 20.0 and 21.4 U/L, 
aspartate aminotransferase (AST) increased by 6.4 U/L and 
8.2 U/L, and γ-glutamyltransferase (GGT) increased by 7.5 
and 9.0 U/L in the placebo-controlled and exposure databases, 
respectively (P # 0.002 for each comparison). In contrast, 
total bilirubin decreased significantly (−1.7 and −1.1 µmol/L) 
in the two databases. Similar increases in ALT and AST have 
been reported in other pediatric studies of olanzapine.30,31 
In the TEOSS trial, such elevations were more common in 
youth treated with olanzapine than those treated with either 
risperidone or molindone. In this study, there also appeared to 
be a tendency for these increases to diminish somewhat with 
continuing treatment.102 Eight (1.8%) of the 454 participants 
in the Lilly adolescent exposure database discontinued treat-
ment due to liver function problems. These elevations may 
reflect nonalcoholic steatohepatitis (nonalcoholic fatty liver 
disease), although imaging studies and long-term follow-up 
is not yet available. In a retrospective chart review of youth 
treated with olanzapine alone, divalproex alone, or the com-
bination of olanzapine and divalproex, 59% of those treated 
with olanzapine alone had at least 1 elevated hepatic enzyme 
over an average of 8 months of treatment while only 26% of 
those treated with divalproex alone did. However, all of those 
treated with the   combination experienced at least 1 elevation 
and 42% of these had persistent elevations throughout the 
treatment period. One of the youth treated with both agents 
developed clinically significant steatohepatitis that resolved 
when the olanzapine was stopped.121
Hyperprolactinemia
In adults, olanzapine has not been associated with sig-
nificant increases in prolactin. However, children and ado-
lescents appear very sensitive to the prolactin-increasing 
effects of all antipsychotics, including olanzapine.122 The Eli 
Lilly placebo databases report acute prolactin increases of 
11.4 µg/L with olanzapine compared with a slight decrease 
with placebo (P , 0.001). In the longer-term exposure 
database, the increase is much more significant at 23.0 µg/L 
compared with a decrease of −4.2 µg/L in the pooled adult Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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data (P = 0.004). Interestingly, fewer female adolescents 
experienced prolactin elevations than male adolescents. Sim-
ilar changes have been described in other clinical trials.30,31 
Further, Wudarsky reported that 7 of 10 youth treated with 
olanzapine had elevations above the upper limits of normal 
for their age and gender. However, prolactin elevations with 
risperidone have consistently been found to be more extreme 
than with olanzapine in pediatric patients.30,31 It appears that 
olanzapine plasma concentration is significantly correlated 
with serum prolactin levels.123 However, most clinical 
  trials do not report high rates of prolactin-related adverse 
events, such as menstrual irregularities, gynecomastia, or 
  galactorrhea. The large Eli Lilly exposure database identi-
fied such problems in only 0.6%–4.2% of participants. The 
long-term consequences of moderate elevations in prolactin 
during adolescence are unknown.
Sedation
Most pediatric trials of olanzapine report high rates of 
sedation ranging from about 40% to 91%.30,31,95,96,100 In the 
Eli Lilly databases, the incidence appears somewhat lower 
(17.4%–19.0%). However, if the reported rates of somnolence 
are generally additive to those of sedation, the rates move 
into the 40% range reported in other studies. Unfortunately, 
sedation often does not resolve in individuals who continue 
long-term treatment.100,102 Sedation can have significant 
impact upon a youth’s ability to participate in school and other 
age-appropriate activities. Less than 1% of youth in Eli Lilly’s 
databases discontinued participation due to sedation.
Extrapyramidal symptoms
Almost all types of extrapyramidal adverse effects, includ-
ing parkinsonian symptoms, dystonia, dyskinesia, tardive 
dyskinesia, akathisia, and neuroleptic malignant syndrome 
(NMS), have been reported in youth treated with olanzapine. 
However, these adverse events appear to occur much less 
often with olanzapine than with other antipsychotics includ-
ing aripiprazole in youth. The incidence in the Lilly exposure 
database was 2.3% for parkinsonian symptoms, 5.5% for 
akathisia, and 1.4% for dyskinetic movements. Generally, 
those symptoms that do occur are minimal to mild. In com-
parative studies, olanzapine is consistently associated with 
fewer and less-severe extrapyramidal adverse events than 
risperidone, haloperidol, or molindone.30,31,100 There is 1 case 
report of persistent dystonic movements emerging during 
olanzapine treatment and persisting up to 6 weeks after switch-
ing to clozapine treatment.124 However, very few children and 
adolescents have been maintained for an extended period on a 
single antipsychotic or followed for sufficiently long periods 
to rigorously assess the medication-specific incidence of this 
late appearing and persistent adverse effect.
Neuroleptic malignant syndrome
NMS is a rare, potentially fatal, and idiosyncratic drug 
reaction that often occurs early in the course of antipsy-
chotic treatment. NMS previously has been  associated with 
the use of classical high-potency neuroleptics.125,126 Case 
reports suggest that NMS resulting from treatment with 
olanzapine and other SGAs has a more insidious course 
than NMS   precipitated by first-generation high-potency 
agents. In   addition,   temperature elevations may emerge late 
in the course.   Cognitive symptoms including agitation and 
delirium may be more prominent. However, there have been 
two case reports of classic NMS occurring during olanzap-
ine monotherapy,127,128 one with olanzapine overdose,129 and 
several in the context of polypharmacy with other psycho-
tropics (as described in two recent reviews).126,130
Hematologic effects
Although clozapine is best known for its risk of hema-
tologic abnormalities, there are many case reports of 
neutropenia being caused by other antipsychotics as well. 
Olanzapine and ziprasidone seem to be more likely than 
the other newer antipsychotics to cause such abnormali-
ties.131 There are some case reports where olanzapine was 
the only medication being taken.132 Consequently, the FDA 
required a label change noting the risk of neutropenia and 
leukopenia with olanzapine treatment in August 2009. 
The label notes that this risk appears to be heightened 
in individuals with a history of blood dyscrasias or low 
white blood cell counts, particularly those induced by 
other drugs or those on drugs that have similar effects. In 
such cases, the patient’s blood count should be monitored 
frequently when treatment is initiated and treatment should 
be interrupted if the absolute neutrophil count drops 
below 1000 cells/cm3. It is unknown whether the risk for 
neutropenia is greater in the pediatric population than in 
the adult population.
Overdose
In adult studies, Lily data of over 3,100 subjects showed 
that the largest ingestion was 300 mg and that person did 
well with supportive care. However, there are multiple other 
reports of fatalities that some believe are related to olanzap-
ine.133–135 There have been at least two fatalities in children 
who have overdosed on olanzapine.136 Often, individuals Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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with olanzapine overdoses develop EPS or NMS, respiratory 
symptoms, and mental status changes.129,137–139 Overdoses in 
pediatric patients are reviewed by Theisen.140 Management 
is   primarily supportive and symptoms may take several days 
to a few weeks to fully resolve.
Olanzapine use in the pediatric 
population
The pattern of olanzapine’s use over time in the US   pediatric 
population relative to other antipsychotics is shown in 
Figure 2. When olanzapine was approved by the FDA in 
1996, it almost immediately began being used in the   pediatric 
population.140–149 However, its use never became as prevalent 
as risperidone’s. Quetiapine’s use was of similar magnitude 
by 2001. However, as data about olanzapine-associated 
weight gain emerged, the FDA issued requirements that SGA 
labels warn about the weight and metabolic risks; the Ameri-
can Diabetes Association and the American   Psychiatric 
Association released a consensus statement indicating that 
olanzapine and clozapine had the greatest risk for such 
side effects and olanzapine use in the pediatric population 
quickly diminished to 5% or less of the total antipsychotics 
prescribed.146,148
Evidence from the CATIE trial that showed a slight 
advantage of olanzapine over other first-line antipsychotics 
in total duration of treatment and symptom response and 
from a first-episode study showing neuroimaging benefits 
compared with haloperidol, as well as the similarities between 
the binding profiles of olanzapine and clozapine, led some 
clinicians to use olanzapine in a few youth with very severe 
or persistent psychotic symptoms.27,29,150 Youth with bipolar 
disorder are even less likely to be treated with olanzapine. In 
a recent study of pediatric bipolar treatment, it was used less 
often than any other antipsychotic (including FGAs).151
Olanzapine appears to be used more frequently in some 
parts of Europe but still to a lesser extent than either risperi-
done or quetiapine. In the CAFEPS longitudinal naturalistic 
study of youth with positive psychotic symptoms about 
15% were treated with olanzapine.101 In Canada, use is also 
somewhat greater than in the United States with about 6000 
children (∼22% of those who are treated with antipsychotics) 
receiving prescriptions for olanzapine annually between 
3
2.5
2
1.5
1
0.5
0
1990 1992 1994 1996 1998 2000 2002 2004 2006
FGA Risperidone Olanzapine
Olanzapine
Quetiapine
Quetiapine
Aripiprazole
Aripiprazole Clozapine Risperidone Ziprasidone
Thioridazine warning Diabetes warning Consensus stmt
M
i
l
l
i
o
n
 
U
S
 
o
u
t
p
u
t
 
v
i
s
i
t
s
/
y
e
a
r
Figure 2 Patterns of antipsychotic use in the pediatric population of the United States. Following the introduction of each second-generation antipsychotic except clozapine, 
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2003 and 2006.147 In countries outside the United States, 
aripiprazole appears to be less frequently used, so olanzapine 
and quetiapine are likely to be viewed as the antipsychotics 
with the least risk for EPS.
Conclusions
Olanzapine has clear efficacy for pedBP and EOSS. However, 
it also appears to have very great potential for promoting 
weight gain, increased insulin secretion, and dyslipidemia 
in children and adolescents. These adverse risks appear to 
be remarkably increased relative to other antipsychotics   
with the possible exception of clozapine. In the light of this 
extreme risk and because there is no compelling evidence 
that olanzapine has greater antipsychotic efficacy than other 
agents in either unselected youth with EOSS and other psy-
chotic illnesses or in treatment-resistant EOSS, we argue that 
olanzapine should not be considered a first-line treatment for 
EOSS. Because there is clear evidence that clozapine has 
superior efficacy to olanzapine in treatment-resistant EOSS, 
we feel clinicians and families should seriously consider a 
trial of clozapine rather than olanzapine in such youth. There 
are no comparative studies examining the mood-stabilizing 
or antimanic properties of olanzapine relative to other SGAs. 
In the absence of any empiric data regarding comparative 
efficacy, olanzapine’s heightened risks for weight gain and 
metabolic dysregulation suggest to the authors that it should 
not be considered a first-line treatment for pedBP either. 
However, because there is no treatment of choice for youth 
with pedBP, who have failed to respond to multiple first-line 
treatments, olanzapine might have a role in treating such 
children and adolescents.
Although olanzapine is unlikely to be used frequently in 
the pediatric population, it remains an alternative for some 
individuals. Such individuals might include those who are 
underweight, have no family history of diabetes or dys-
lipidemia, or are particularly sensitive to the extrapyramidal 
side effects of antipsychotics with more potent dopamine 
D2 receptor binding. These conclusions are supported by 
the FDA’s recent decision to approve olanzapine for the 
treatment of adolescents with schizophrenia or manic/mixed 
states in bipolar disorder, provided clinicians and families 
carefully consider prescribing other agents first due to olan-
zapine’s marked risks for significant weight gain and lipid 
dysregulation in adolescents.
Olanzapine has played a critical role in alerting scientists and 
the public to the metabolic consequences of most antipsychot-
ics, particularly within children and adolescents. The consistent 
weight and metabolic changes observed in olanzapine-treated 
youth spurred investigations of such effects among youth treated 
with other antipsychotics and provided a strong impetus for 
long-term studies of antipsychotic tolerability in youth.
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